System Guide
Back to Search Results

Search Results

Display Options
Display Options
Select Fields
Export Results to CSV Create Report 0
+ Add all results to report

Report Produced: 07/26/2025 19:14 PM

Report Question ID Question
20071043 Multiplicity Counter: Are in situ tumors diagnosed more than 60 days after invasive tumors of the same site and histology included in the Multiplicity Counter?
20081006 Multiplicity Counter: Is there a time frame for the Multiplicity Counter or is it related to the duration for counting new tumors (i.e. 5 years for breast, etc) to capture the number of "local recurrences"?
20081069 Multiplicity Counter: Should this field be coded to 99 for cases of familial adenomatous polyposis (FAP)? See Discussion.
20061050 Neoadjuvant Treatment/Date Therapy Initiated--Breast: If Tamoxifen has been used since 2000 for the treatment of hyperplasia, should it be coded as neoadjuvant treatment for a 2004 diagnosis of breast cancer?
20041007 Other Cancer-Directed Therapy--Hematopoietic, NOS: How is this field coded when transfusions are used to treat acute leukemia or thrombocythemia?
20031210 Other Cancer-Directed Therapy--Hematopoietic, NOS: Is there a hierarchy for selecting which code to use when a patient receives more than one type of "other treatment"? See Description.
20031142 Other Therapy/Immunotherapy--Hematopoietic, NOS: How should erythropoietin be coded for leukemia or other hematopoietic diseases?
20051110 Other Therapy: Can herbal therapy be coded when used as a single therapy or when used in combination with conventional therapy as a complimentary treatment? See Discussion.
20031045 Other Therapy: How do we classify "thalidomide" when it is given as cancer directed therapy?
20000452 Other Therapy: What code is used to represent "gene" therapy? See discussion.